# A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer

> **NCT00488722** · NA · UNKNOWN · sponsor: **Tianjin Medical University**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Zoladex

## Key facts

- **NCT ID:** NCT00488722
- **Lead sponsor:** Tianjin Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2009-03
- **Target enrollment:** — (—)
- **Last updated:** 2007-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488722, "A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00488722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*